Viatris (VTRS) Stock Overview
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
VTRS Community Fair Values
Create NarrativeSee what 78 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$39.24
FV
56.9% undervalued intrinsic discount99
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Viatris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.92 |
| 52 Week High | US$17.53 |
| 52 Week Low | US$8.19 |
| Beta | 0.87 |
| 1 Month Change | 25.61% |
| 3 Month Change | 6.08% |
| 1 Year Change | 88.84% |
| 3 Year Change | 80.58% |
| 5 Year Change | 4.77% |
| Change since IPO | 2,659.44% |
Recent News & Updates
Recent updates
Seeking Alpha • May 11
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking Alpha
Narrative Update • May 03
VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential
Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
Narrative Update • Apr 19
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.Narrative Update • Apr 04
VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.Narrative Update • Mar 21
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
Narrative Update • Mar 07
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.Narrative Update • Feb 20
VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.Narrative Update • Feb 06
VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.Narrative Update • Jan 23
VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.Narrative Update • Jan 09
VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.Narrative Update • Dec 25
VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.Narrative Update • Dec 11
VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.Narrative Update • Nov 27
VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.Narrative Update • Nov 13
VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.Narrative Update • Oct 30
VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.Narrative Update • Oct 15
Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.Narrative Update • Aug 27
Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
New Narrative • Apr 22
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Seeking Alpha • Feb 27
Viatris: One Swallow Doesn't Make A Summer
Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking AlphaSeeking Alpha • Nov 08
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Summary Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%. Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act. Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward. With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth. Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Summary Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S ratios suggesting a “screaming buy,” falling revenues and substantial debt challenge Viatris' growth prospects. CEO Scott Smith's “Phase 2” strategy focuses on new product launches and debt reduction, aiming to offset declining sales of older generics and established brands. Viatris' future growth hinges on its innovative pipeline and global infrastructure, with potential blockbuster drugs and a streamlined business model promising profitability and shareholder returns. Read the full article on Seeking AlphaShareholder Returns
| VTRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 11.3% | -1.5% | 2.6% |
| 1Y | 88.8% | 30.4% | 26.2% |
Return vs Industry: VTRS exceeded the US Pharmaceuticals industry which returned 33.5% over the past year.
Return vs Market: VTRS exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| VTRS volatility | |
|---|---|
| VTRS Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VTRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTRS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1961 | 30,000 | Scott Smith | www.viatris.com |
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
Viatris Inc. Fundamentals Summary
| VTRS fundamental statistics | |
|---|---|
| Market cap | US$20.00b |
| Earnings (TTM) | -US$296.50m |
| Revenue (TTM) | US$14.56b |
1.4x
P/S Ratio-66.5x
P/E RatioIs VTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTRS income statement (TTM) | |
|---|---|
| Revenue | US$14.56b |
| Cost of Revenue | US$8.76b |
| Gross Profit | US$5.80b |
| Other Expenses | US$6.09b |
| Earnings | -US$296.50m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 39.82% |
| Net Profit Margin | -2.04% |
| Debt/Equity Ratio | 97.8% |
How did VTRS perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield-188%
Payout RatioDoes VTRS pay a reliable dividends?
See VTRS dividend history and benchmarks| Viatris dividend dates | |
|---|---|
| Ex Dividend Date | May 22 2026 |
| Dividend Pay Date | Jun 17 2026 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 35 days |
Does VTRS pay a reliable dividends?
See VTRS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 19:42 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viatris Inc. is covered by 31 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |